Literature DB >> 22156215

Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder.

Scott Letendre1.   

Abstract

HIV-associated neurocognitive disorder (HAND) is the result of neural damage caused by HIV replication and immune activation. Potent antiretroviral therapy has reduced the prevalence of severe HAND but not mild to moderate HAND. Brief symptom questionnaires, screening tests, and neuropsychological tests can be used with relative ease in the clinic to identify cognitive and neurologic deficits and to track patient status. Increasing data on pharmacokinetics of antiretrovirals in cerebrospinal fluid (CSF) have permitted formulation of central nervous system (CNS) penetration-effectiveness (CPE) rankings for single drugs and combinations. Available data indicate that regimens with higher CPE scores are associated with lower HIV RNA levels in CSF and improvement in neurocognitive functioning. This article summarizes a presentation by Scott Letendre, MD, at the IAS-USA live continuing medical education course held in San Francisco in May 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156215      PMCID: PMC4666587     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  27 in total

1.  Motor based assessment of neurocognitive functioning in resource-limited international settings.

Authors:  Thomas D Parsons; Steven Rogers; Colin Hall; Kevin Robertson
Journal:  J Clin Exp Neuropsychol       Date:  2007-01       Impact factor: 2.475

2.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

3.  Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

Authors:  Aylin Yilmaz; Victoria Watson; Laura Else; Magnus Gisslèn
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

4.  Clinical validation of the NeuroScreen.

Authors:  Ronald J Ellis; Scott R Evans; David B Clifford; Lauren R Moo; Justin C McArthur; Ann C Collier; Constance Benson; Ron Bosch; David Simpson; Constantin T Yiannoutsos; Yijun Yang; Kevin Robertson
Journal:  J Neurovirol       Date:  2005-12       Impact factor: 2.643

5.  Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

Authors:  Andrea Antinori; Carlo Federico Perno; Maria Letizia Giancola; Federica Forbici; Giuseppe Ippolito; Richard M Hoetelmans; Stephen C Piscitelli
Journal:  Clin Infect Dis       Date:  2005-11-10       Impact factor: 9.079

6.  Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine.

Authors:  M Cherner; S Letendre; R K Heaton; J Durelle; J Marquie-Beck; B Gragg; I Grant
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

7.  Low atazanavir concentrations in cerebrospinal fluid.

Authors:  Brookie M Best; Scott L Letendre; Eileen Brigid; David B Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; David M Simpson; Ronald Ellis; Edmund V Capparelli; Igor Grant
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

8.  Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

Authors:  Christina M Marra; Yu Zhao; David B Clifford; Scott Letendre; Scott Evans; Katherine Henry; Ronald J Ellis; Benigno Rodriguez; Robert W Coombs; Giovanni Schifitto; Justin C McArthur; Kevin Robertson
Journal:  AIDS       Date:  2009-07-17       Impact factor: 4.177

9.  Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.

Authors:  L A Cysique; F Vaida; S Letendre; S Gibson; M Cherner; S P Woods; J A McCutchan; R K Heaton; R J Ellis
Journal:  Neurology       Date:  2009-05-27       Impact factor: 9.910

10.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Authors:  Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant
Journal:  J Neurovirol       Date:  2010-12-21       Impact factor: 2.643

View more
  112 in total

1.  Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.

Authors:  Andrew J Ocque; Colleen E Hagler; Gene D Morse; Scott L Letendre; Qing Ma
Journal:  J Pharm Biomed Anal       Date:  2018-04-23       Impact factor: 3.935

2.  HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies.

Authors:  Mark R Etherton; Jennifer L Lyons; Kevin L Ard
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

3.  Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Authors:  Eric H Decloedt; Bernd Rosenkranz; Gary Maartens; John Joska
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

Review 4.  HIV-associated cellular senescence: A contributor to accelerated aging.

Authors:  Justin Cohen; Claudio Torres
Journal:  Ageing Res Rev       Date:  2016-12-23       Impact factor: 10.895

5.  HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy.

Authors:  Lauren N Bowen; Richa Tyagi; Wenxue Li; Tariq Alfahad; Bryan Smith; Mary Wright; Elyse J Singer; Avindra Nath
Journal:  Neurology       Date:  2016-09-24       Impact factor: 9.910

6.  Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence.

Authors:  Albert M Anderson; Melinda K Higgins; Raymond L Ownby; Drenna Waldrop-Valverde
Journal:  AIDS Care       Date:  2014-12-06

7.  The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study.

Authors:  María J Marquine; Jessica L Montoya; Anya Umlauf; Pariya L Fazeli; Ben Gouaux; Robert K Heaton; Ronald J Ellis; Scott L Letendre; Igor Grant; David J Moore
Journal:  Clin Infect Dis       Date:  2016-05-19       Impact factor: 9.079

8.  Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.

Authors:  Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

9.  Neuronal toxicity in HIV CNS disease.

Authors:  Jane Kovalevich; Dianne Langford
Journal:  Future Virol       Date:  2012-07-01       Impact factor: 1.831

Review 10.  Protease resistant protein cellular isoform (PrP(c)) as a biomarker: clues into the pathogenesis of HAND.

Authors:  Bezawit Megra; Eliseo Eugenin; Toni Roberts; Susan Morgello; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-25       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.